Compare EVR & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVR | DVA |
|---|---|---|
| Founded | 1995 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7B | 14.9B |
| IPO Year | 2006 | 2003 |
| Metric | EVR | DVA |
|---|---|---|
| Price | $340.00 | $235.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $359.38 | $156.75 |
| AVG Volume (30 Days) | 360.3K | ★ 701.3K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 54.74 | N/A |
| EPS | ★ 7.20 | 2.87 |
| Revenue | $3,880,084,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $22.69 | $3.85 |
| Revenue Next Year | $13.31 | $3.07 |
| P/E Ratio | ★ $48.07 | $81.55 |
| Revenue Growth | ★ 29.49 | 6.46 |
| 52 Week Low | $265.87 | $101.00 |
| 52 Week High | $388.71 | $239.64 |
| Indicator | EVR | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 72.99 |
| Support Level | $330.28 | $145.58 |
| Resistance Level | $353.81 | $239.64 |
| Average True Range (ATR) | 11.48 | 6.61 |
| MACD | -0.22 | -0.53 |
| Stochastic Oscillator | 37.92 | 84.30 |
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. Evercore operates globally, with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.